Sectors
IONS
Ionis Pharmaceuticals, Inc.
44.44
2 x 42.26
2 x 48.48
bid
ask
-
2.31
4.94%
2 @ 07:52 PM
44.53 +0.09 (0.20%)
| Ytd | -43.83% | |
| 1y | -28.02% |
44.29
day range
46.75
44.27
52 week range
86.74
| Open | 46.66 | Prev Close | 46.75 | Low | 44.29 | High | 46.75 | Mkt Cap | 7.39B |
| Vol | 7.37M | Avg Vol | 3.53M | EPS | -3.48 | P/E | N/A | Forward P/E | -39.95 |
| Beta | 0.42 | Short Ratio | 9.20 | Inst. Own | 110.53% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-04 | 50-d Avg | 55.97 | 200-d Avg | 72.18 | 1yr Est | 83.82 |
| Income Statement | |||
| Total Revenue | 267.95M | ||
| Revenues (USD) | 267.95M | ||
| Cost of Revenue | 2.74M | ||
| Gross Profit | 265.21M | ||
| Operating Expenses | 367.50M | ||
| Research and Development Expense | 217.11M | ||
| Selling, General and Administrative Expense | 150.40M | ||
| Operating Income | -102.29M | ||
| Interest Expense | 22.12M | ||
| Income Tax Expense | 1.26M | ||
| Net Income | -114.65M | ||
| Net Income Common Stock | -114.65M | ||
| Net Income Common Stock (USD) | -114.65M | ||
| Consolidated Income | -114.65M | ||
| Earnings per Basic Share | -0.69 | ||
| Earnings per Basic Share (USD) | -0.69 | ||
| Earnings per Diluted Share | -0.69 | ||
| Earning Before Interest & Taxes (EBIT) | -91.26M | ||
| Earning Before Interest & Taxes (USD) | -91.26M | ||
| Weighted Average Shares | 165.42M | ||
| Weighted Average Shares Diluted | 165.42M | ||
| Balance Sheet | |||
| Cash and Equivalents | 350.07M | ||
| Cash and Equivalents (USD) | 350.07M | ||
| Investments | 1.70B | ||
| Investments Current | 1.70B | ||
| Trade and Non-Trade Receivables | 58.85M | ||
| Current Assets | 2.49B | ||
| Property, Plant & Equipment Net | 386.69M | ||
| Total Assets | 2.99B | ||
| Total Debt | 1.61B | ||
| Current Liabilities | 315.64M | ||
| Debt Non-Current | 1.61B | ||
| Total Liabilities | 2.55B | ||
| Accumulated Retained Earnings (Deficit) | -2.84B | ||
| Accumulated Other Comprehensive Income | -33.90M | ||
| Shareholders Equity | 439.74M | ||
| Shareholders Equity (USD) | 439.74M | ||
| Assets Non-Current | 503.23M | ||
| Total Debt (USD) | 1.61B | ||
| Deferred Revenue | 136.87M | ||
| Inventory | 50.83M | ||
| Liabilities Non-Current | 2.24B | ||
| Trade and Non-Trade Payables | 47.70M | ||
| Tax Liabilities | 2.88M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 7.64M | ||
| Net Cash Flow from Financing | -412.29M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 176.68M | ||
| Capital Expenditure | -16.08M | ||
| Issuance (Purchase) of Equity Shares | 20.26M | ||
| Issuance (Repayment) of Debt Securities | -432.55M | ||
| Net Cash Flow from Investing | 23.50M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 41.73M | ||
| Net Cash Flow from Operations | 565.53M | ||
| Effect of Exchange Rate Changes on Cash | -50.00K | ||
| Share Based Compensation | 45.60M | ||